



Collaboration to Harmonize Antimicrobial Registry Measures (CHARM) to Track Outpatient Antibiotic Use

Michael E. Klepser, PharmD, FCCP, FIDP
Professor, Ferris State University College of Pharmacy
Senior Director, CAPE
Senior Director, CHARM

**At the end of the session
the attendee will be
able to:**

1. Discuss the purpose of the CHARM project
2. Summarize how CHARM can support a One Health approach to antibiotic use.
3. Outline the plans to expand CHARM into Illinois.

What is CHARM?

- The Collaboration to Harmonize Antimicrobial Registry Measures (CHARM) is a collaborative effort to utilize data from partner institutions' electronic medical records (EMR) to quantify and assess local antimicrobial prescribing practices.
 - By assisting partners understand their current prescribing practices, antimicrobial stewardship opportunities can be targeted and the impact of initiatives measured.
 - CHARM allows participating entities to benchmark their usage patterns against other systems.
- Supported by the Michigan Department of Health and Human Services (MDHHS).



Collaboration to Harmonize
Antimicrobial Registry Measures

- **Mission:** Provide real-time guidance and direction to clinicians and health systems to optimize antibiotic use.
- **Senior Director:** Michael Klepser, PharmD
- **Director:** Minji Sohn, PhD
- **Director of Research:** Benjamin Pontefract, PharmD
- **Data Analyst:** Kushal Dhal, MS
- **Interns:** Cameron Lakatos and Jessica Swailes

The CHARM Process

- CHARM was established in 2014, at the Ferris State University College of Pharmacy, in an effort to create a simple means for health systems to gather data and describe outpatient antibiotic usage patterns in a standardized fashion.



CHARM Process

- Extract data
 - Limited and masked data set
 - Identify episode of antibiotic use
 - Serves as the anchor for the collection of other relevant data
 - Link to a diagnosis (ICD-10 code)

Fields	
Masked Patient ID	Insurance Type
Facility/Clinic	Provider
Sex	Provider Type
Race/Ethnicity	Encounter Type
Date of Encounter	Antibiotic Allergies
Age	Renal Function
Body weight	Indication Code
Prescription	Indication Name
Antibiotic Name	Antibiotic Dose
Antibiotic Unit	Antibiotic Quantity
CPT Code	Test Results

CHARM Process

- Summarize and analyze data
 - Quantify antibiotic use
 - Antibiotic prescriptions per 1,000 clinic visits
 - Antibiotic prescriptions per 1,000 clinic patients
 - Determine if the antibiotic selected and indication are in concordance with published guidelines, FDA-approved indications, and/or site-specific treatment pathways for the associated indication.

CHARM Process

- Summarize and analyze data
 - For agents that are concordant with respect to indication, determine dosing concordance



Prescribed Therapeutic Regimen (PTR)

$$PTR = (Dose_{Prescribed} \times Duration_{Prescribed} \times Frequency_{Prescribed})$$

Recommended Therapeutic Regimen (RTR_{Min/Max})

$$RTR = (Dose_{Recommended} \times Duration_{Recommended} \times Frequency_{Recommended})$$

CHARM Process



**Determine
driver of
discordance**



Collaboration to Harmonize Antimicrobial Registry Measures



Patient Demographics

Demographics

Medication Details

Diagnosis Details

Drug Choice

Dosing Evaluation

Facility-Provider Breakdowns

Gender
 Female
 Male

Age Group
 ADULT
 CHILD

Facility
All

Provider
All

Medication
All





Diagnosis
All

Facilities
900

Antibiotic Prescriptions
1,290,731

Antibiotic Receiving Patients
389K

Antibiotic Receiving Encounters
739K





Collaboration to Harmonize Antimicrobial Registry Measures



Medication Analysis

Demographics

Medication Details

Diagnosis Details

Drug Choice

Dosing Evaluation

Facility-Provider Breakdowns

Gender
 Female
 Male





Age Group
 ADULT
 CHILD

Facility
 All

Provider
 All

Medication
 All

Diagnosis
 All








Collaboration to Harmonize Antimicrobial Registry Measures



Drug Choice Concordance

- Demographics
- Medication Details
- Diagnosis Details
- Drug Choice**
- Dosing Evaluation
- Facility-Provider Breakdowns
- Gender
 - Female
 - Male
- Age Group
 - ADULT
 - CHILD

Facility:
 Provider:
 Medication:
 Diagnosis:





Collaboration to Harmonize Antimicrobial Registry Measures

- Demographics
- Medication Details
- Diagnosis Details
- Drug Choice
- Dosing Evaluation
- Facility-Provider Breakdowns
- Gender
 - Female
 - Male
- Age Group
 - ADULT
 - CHILD

Dosing Concordance

Facility

All

Provider

All

Medication

All

Diagnosis

UTI - Cystitis

% Of Concordant Dosing out of Concordance Drug Choice

3.21%

Number of #Rx with Concordant Drug Choice

10K

% of Concordant Dosing by Year, Quarter and Month

Dosing Concordance by Antibiotic Drug

Antibiotic Name	Concordant Dosing	Higher Than Recommended	Incomplete Information	Lower Than Recommended
NITROFURANTOIN	18K	3K	0	0
CIPROFLOXACIN	6K	4K	0	0
CEFDINIR	0	0	0	0
FOSFOMYCIN	0	0	0	0
LEVOFLOXACIN	0	0	0	0
CEFPODOXIME	0	0	0	0
CEFEPIME	0	0	0	0

Average Length of Therapy (Days)

Average Daily Dose (mg)

Recommended Therapeutic Regimen (RTR)

Indication	Rx Name	Min Duration (days)	Max Duration (days)	RTR Min	RTR Max	kg_based_max	kg_based_min
UTI - Cystitis	CIPROFLOXACIN	3.00	3.00	1,500.00	1,500.00	0.00	0.00



Collaboration to Harmonize Antimicrobial Registry Measures



- Demographics
- Medication Details
- Diagnosis Details
- Drug Choice
- Dosing Evaluation
- Facility-Provider Breakdowns**
- Gender
 - Female
 - Male
- Age Group
 - ADULT
 - CHILD


Facility-Provider Breakdowns

Provider Summary

Provider_name	Prescriptions	% of Prescriptions
639	1,880	40.13%
2278	753	16.07%
2432	521	11.12%
284	393	8.39%
762	186	3.97%
1497	166	3.54%
1570	150	3.20%
3894	106	2.26%
295	88	1.88%
2139	64	1.37%
1736	53	1.13%
Total	4,685	100.00%

Facility Summary

facility	Prescriptions	% of Prescriptions
837	1,880	99.21%
568	13	0.69%
588	2	0.11%
Total	1,895	100.00%



Diagnosis Group Summary

Diagnosis_Grouping	Prescriptions	% of Prescriptions
Non-infectious	4,094	46.70%
UTI - Cystitis	1,880	21.45%
Acute Pharyngitis	1,310	14.94%
Acute Sinusitis	908	10.36%
Candidiasis - Miscellaneous	808	9.22%
SSTI - Cellulitis	793	9.05%
Cough	775	8.84%
Otitis Media	769	8.77%
GU - Female	645	7.36%
Unspecified Sexually Transmitted Infection	561	6.40%
GU - Miscellaneous	286	3.26%
SSTI - Abscess	282	3.22%
UTI - Unspecified	220	2.51%
SSTI - Miscellaneous	195	2.22%
Upper Respiratory	179	2.04%

Antibiotic Medication

Antibiotic	Prescriptions	% of Prescriptions
CIPROFLOXACIN	659	36.96%
NITROFURANTOIN	346	19.41%
CEPHALEXIN	304	17.05%
METRONIDAZOLE	272	15.26%
AMOXICILLIN	67	3.76%
AZITHROMYCIN	40	2.24%
DOXYCYCLINE	27	1.51%
AMOXICILLIN-CLAVULANATE	23	1.29%
CLINDAMYCIN	23	1.29%
LEVOFLOXACIN	6	0.34%
MUPIROCI	6	0.34%
OXFLOXACIN	6	0.34%
CEFDINIR	4	0.22%





Collaboration to Harmonize Antimicrobial Registry Measures



Demographics

Medication Details

Diagnosis Details

Drug Choice

Dosing Evaluation

Facility-Provider Breakdowns

HEDIS

Gender

Female

Male

Age Group

ADULT

CHILD

HEDIS: Acute Bronchitis (AB) and Upper Respiratory Infection (URI)

Hedis Diagnosis Category

Acute Bronchitis

Payer Type

All

Race

All

Facility

All

#Hedis Encounters

28,477


% Not Receiving Abx

36.74%


#Hedis Abx Encounters

18,015


Encounters by Age Range




% Not Receiving Antibiotic by Year, Quarter and Month



Hedis Encounters by Race



Hedis Encounters by Ethnicity



Antibiotic Given for AB

Antibiotic	#Encounters	% of Total
Azithromycin	6,841	37.97%
Doxycycline	2,613	14.50%
Cefdinir	2,358	13.09%
Amoxicillin	1,605	8.91%
Amoxicillin-Clavulanate	1,507	8.37%
Levofloxacin	1,437	7.98%
Cephalexin	784	4.35%
Fluconazole	378	2.10%
Cefprozil	329	1.83%
Cefuroxime	182	1.01%
Oseltamivir	165	0.92%
Total	18,015	100.00%

Prescriber Level Data

Prescriber	#Encounters	## Not Receiving ABx
1003	1	100.00%
1005	2	
1006	222	34.23%
1008	2	100.00%
1010	9	77.78%
1011	7	14.29%
1012	334	16.17%
1013	11	54.55%
1014	14	100.00%
1015	517	14.70%
1016	2	100.00%
Total	28,477	36.74%





Collaboration to Harmonize Antimicrobial Registry Measures



HEDIS: Acute Bronchitis (AB) and Upper Respiratory Infection (URI)

- Demographics
- Medication Details
- Diagnosis Details
- Drug Choice
- Dosing Evaluation
- Facility-Provider Breakdowns
- HEDIS**
- Gender
 - Female
 - Male
- Age Group
 - ADULT
 - CHILD





Hedis Diagnosis Category
Acute Bronchitis

Payer Type
All

Race
All

Facility
All

#Hedis Encounters: **334** % Not Receiving Abx: **16.17%** #Hedis Abx Encounters: **280**



Antibiotic	#Encounters	% of Total
Azithromycin	125	44.64%
Doxycycline	110	39.29%
Levofloxacin	25	8.93%
Cefdinir	7	2.50%
Cefuroxime	4	1.43%
Fluconazole	3	1.07%
Ciprofloxacin	2	0.71%
Clarithromycin	2	0.71%
Oseltamivir	2	0.71%
Amoxicillin	1	0.36%
Bactrim	1	0.36%
Clindamycin	1	0.36%
Total	280	100.00%


Prescriber	#Encounters	##% Not Receiving ABx
1003	1	100.00%
1005	2	0%
1006	222	34.23%
1008	2	100.00%
1010	9	77.78%
1011	7	14.29%
1012	334	16.17%
1013	11	54.55%
1014	14	100.00%
1015	517	14.70%
1016	2	100.00%
Total	28,477	36.74%



CHARM Logistics

Initial meeting with Ferris and Site AMS champions

- **Data Use Agreement (DUA) is established between the health system and Ferris.**



Ferris works with Site's IT dept for data extraction and transfer

- **Data is extracted in a .xlsx or .csv format.**
- **To transfer data, health system's IT staff uploads the extract to a Ferris' OneDrive for Business folder.**
- **Clinician members provide input during the extract process.**



Ferris analyzes data and provide clinic with interactive dashboards

- **Once developed, we simply feed new data into the dashboard.**
- **Revisions/tweaks are made as needed.**

CHARM Logistics

- Initial data transfer can include significant historical data
- Subsequent data transfers occur monthly to quarterly
- Dashboard is updated as new data is submitted

Limitations




- Diagnoses are not verified
 - ICD-10 based diagnosis may be subject to coding bias
 - Not all systems link antibiotic prescriptions to diagnosis
- Renal function data are often not available
- Allergy data is not reliable

Advantages of CHARM

- Timely and actionable reports
 - Minimal data lag
 - Highly interactive dashboard allows for identification of areas for improvement
 - Allows for determination of intervention effectiveness
- Uses EHR data (no fee to acquire data, all-payer encounters)
- Not limited to a specific EHR software
- Highly granular reports
 - Data can be examined at various levels including facility, provider, and patient levels
- Flexibility
 - Assessment of antibiotic appropriateness can use site specific algorithms

- **Activities:**
 - Support dashboards to track and assesses concordance of outpatient antibiotic for 17 health systems in Michigan and 8 health systems in other states.

CHARM Partners






Collaboration to Harmonize
Antimicrobial Registry Measures

- **Partners:**
 - Health system partners include:
 - Large academic health systems
 - Small independent health systems
 - federally qualified health centers
 - Critical access systems
 - Indian nation health systems

CHARM Partners






Collaboration to Harmonize
Antimicrobial Registry Measures

- **Activities:**

- Maintain Michigan statewide benchmarking dashboard of outpatient antibiotic use
- Developed a HEDIS progress dashboard for
 - Appropriate testing for pharyngitis
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis
 - Appropriate Treatment for Upper Respiratory Infection
 - Antibiotic Utilization for Respiratory Conditions
- Support numerous ongoing research projects
- Supports GLID and OASIS

CHARM Partners





Collaboration to Harmonize
Antimicrobial Registry Measures

- **Impact of CHARM**
 - Track approximately 65% of outpatient antibiotic prescriptions in Michigan.
 - Provide education on best practices for outpatient antimicrobial stewardship (Outpatient Antimicrobial Stewardship Innovations Symposium – OASIS)
 - Promotes and supports research among partner institutions
 - Knowledge dissemination
 - Numerous publications in medical journals and invited presentations
 - 21 projects presented at national meetings



Collaboration to Harmonize
Antimicrobial Registry Measures

- **Future Directions for CHARM**
 - Develop provider report cards that can be auto-generated.
 - Pilot initiatives to evaluate if we can detect the impact of interventions on HEDIS measures.
 - Develop support services such as tele-antimicrobial stewardship programs for FQHC's, critical access, and resource limited health systems.
 - Examine data related to SDoH to evaluate areas for improvement in health equity.
 - Continue to expand into other states and secure funding to allow us to develop national dashboards for benchmarking.



Collaboration to Harmonize
Antimicrobial Registry Measures

- **Future Directions for CHARM**
 - Dentistry
 - Currently have data from health system dental practices.
 - Obtained funding to expand into private dental practices.





Collaboration to Harmonize
Antimicrobial Registry Measures

- **Future Directions for CHARM**
 - Veterinary Medicine
 - Pilot with Michigan State University School of Veterinary Medicine
 - Collect data from veterinary hospitals and clinics





Collaboration to Harmonize
Antimicrobial Registry Measures

- **CHARM and One Health**

- Expand antimicrobial stewardship into dental practices.
- Support antimicrobial stewardship in veterinary medicine.
 - Superimpose utilization patterns between humans and animals.
 - Correlate antibiotic use in one species with pathogens/infections in other species.

Extending CHARM into Illinois

- Currently approaching health systems to participate in a pilot of CHARM.
 - Have identified a medical center that we are working to onboard.
 - Preliminary talks have occurred with 5 health systems about participation.
- Seek to expand to all interested parties in Illinois.
 - Medical
 - Dental
 - Veterinary



Extending CHARM into Illinois

- Looking for interested partners.
- Goal is to have 8-10 health systems onboarded by 2026.
 - Develop statewide benchmarking map.





**Collaboration to Harmonize
Antimicrobial Registry
Measures (CHARM)**

Michael E. Klepser, PharmD, FCCP, FIDP

Professor

Ferris State University College of Pharmacy

***Senior Director, Collaboration to Harmonize
Antimicrobial Registry Measures (CHARM)***

25 Michigan Ave, Suite 7000

Grand Rapids, MI 49503

Email: michaelklepser@ferris.edu

Webpage: <https://www.ferris.edu/charm.htm>